Scancell Holdings

London Stock Exchange

Scancell Holdings appoints Dr. Phil L’Huillier as new CEO
ByNNR October 22, 2024October 22, 2024

LONDON: Scancell Holdings plc (AIM: SCLP), a developer of cancer immunotherapies, has appointed Dr. Phil L’Huillier as the new Chief Executive Officer, effective November 18, 2024. Dr. L’Huillier, previously CEO of CatalYm GmbH, brings extensive experience in expanding investor bases…

Read More Scancell Holdings appoints Dr. Phil L’Huillier as new CEO
London Exchange

Scancell initiates development of novel DNA vaccine against COVID-19
ByNNR April 24, 2020October 24, 2023

LONDON: Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of…

Read More Scancell initiates development of novel DNA vaccine against COVID-19